Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MGTX | US
-0.08
-1.89%
Healthcare
Biotechnology
30/06/2024
04/10/2024
4.15
4.16
4.16
4.07
MeiraGTx Holdings plc a clinical stage gene therapy company focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases including inherited retinal diseases and large degenerative ocular diseases neurodegenerative diseases and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia X-linked retinitis pigmentosa and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals Inc. for the research development and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York New York.
View LessSmallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
39.3%1 month
32.4%3 months
64.5%6 months
54.0%-
1.58
4.11
1.09
0.33
-3.29
38.96
-
-155.31M
320.31M
320.31M
-
-16.28K
-
-92.00
-91.51
10.62
3.49
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.50
Range1M
0.62
Range3M
1.54
Rel. volume
0.43
Price X volume
301.78K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
INZY | INZY | Biotechnology | 5.17 | 346.90M | 2.78% | n/a | 49.47% |
Nautilus Biotechnology Inc. | NAUT | Biotechnology | 2.71 | 339.86M | -0.73% | n/a | 13.86% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 6.49 | 337.66M | 2.69% | n/a | 0.38% |
AC Immune SA | ACIU | Biotechnology | 3.38 | 334.42M | -2.87% | n/a | 0.00% |
XOMA Corporation | XOMA | Biotechnology | 27.64 | 323.51M | 0.95% | n/a | 121.93% |
ADC Therapeutics SA | ADCT | Biotechnology | 3.29 | 318.10M | 8.22% | n/a | -94.48% |
Aldeyra Therapeutics Inc | ALDX | Biotechnology | 5.34 | 317.31M | 0.75% | n/a | 15.90% |
Cerus Corporation | CERS | Biotechnology | 1.7 | 315.00M | 0.59% | n/a | 199.34% |
Immutep Limited | IMMP | Biotechnology | 2.05 | 314.34M | -3.07% | n/a | 0.84% |
Monte Rosa Therapeutics Inc | GLUE | Biotechnology | 5.09 | 312.39M | -5.57% | n/a | 19.74% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.29 | 0.76 | Cheaper |
Ent. to Revenue | 38.96 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 4.11 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 64.53 | 74.67 | Par |
Debt to Equity | 1.09 | -1.82 | Expensive |
Debt to Assets | 0.33 | 0.26 | Expensive |
Market Cap | 320.31M | 3.73B | Emerging |